CPIX CUMBERLAND PHARMACEUTICALS INC

Nasdaq cumberlandpharma.com


$ 1.89 $ -0.01 (-0.79 %)    

Thursday, 20-Nov-2025 15:08:40 EST
QQQ $ 589.74 $ -22.00 (-3.6 %)
DIA $ 459.95 $ -6.93 (-1.44 %)
SPY $ 656.31 $ -16.59 (-2.47 %)
TLT $ 89.18 $ 0.19 (0.22 %)
GLD $ 375.06 $ -0.12 (-0.03 %)
$ 1.92
$ 1.91
$ 1.88 x 10
$ 1.94 x 109
$ 1.89 - $ 1.97
$ 1.04 - $ 7.25
73,107
na
28.72M
$ 0.14
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 cumberland-q3-adj-eps-006-down-from-002-yoy-sales-8292m-down-from-9086m-yoy

Cumberland (NASDAQ:CPIX) reported quarterly losses of $(0.06) per share. This is a 200 percent decrease over losses of $(0.02) ...

Core News & Articles

 Cumberland to expand its gastroenterology offerings with the market-leading Helicobacter pylori therapyNASHVILLE, Tenn., Oct. ...

 cumberland-pharma-adds-potent-antibiotic-vibativ-to-national-group-purchasing-agreement-with-premier

Premier Membership includes 4,350 U.S. HospitalsNASHVILLE, Tenn., Oct. 13, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc....

 cumberland-pharmaceuticals-ibuprofen-injection-receives-mexican-regulatory-approval-to-treat-pain-and-fever-pisa-to-roll-out-product-in-mexico

Injectable Ibuprofen Approved for Treating Pain & FeverNASHVILLE, Tenn., Oct. 1 , 2025 /PRNewswire/ -- Cumberland Pharmaceu...

 correction-cumberland-q2-adj-eps-002-up-from-001-yoy-sales-10838m-up-from-9849m-yoy

Cumberland (NASDAQ:CPIX) reported quarterly earnings of $0.02 per share. This is a 100 percent increase over earnings of $0.01 ...

 cumberland-pharma-announces-availability-of-vibativ-4-vial-starter-pak-through-new-contract-with-vizient

Vizient serves more than 65% of the nation's acute care providers, including 97% of academic medical centersNASHVILLE, Tenn...

 cumberland-pharma-presents-latest-results-from-phase-2-fight-dmd-trial-evaluating-ifetroban-oral-therapy-for-dmd-heart-disease-at-ppmd-conference-in-las-vegas

New pharmacokinetic and cardiac biomarker data further demonstrate ifetroban's potential to protect the heart and reduce ca...

 cumberland-pharmaceuticals-and-qureight-partner-to-advance-idiopathic-pulmonary-fibrosis-treatment-research

Cumberland leveraging Qureight's deep-learning AI platform for its Phase II FIGHTING FIBROSIS™ clinical trial

 cumberland-q1-adj-eps-016-up-from-005-yoy-sales-1171m-up-from-850m-yoy

Cumberland (NASDAQ:CPIX) reported quarterly earnings of $0.16 per share. This is a 420 percent increase over losses of $(0.05) ...

 cumberland-pharmaceuticals-announced-results-from-its-phase-2-fight-dmd-clinical-trial-were-selected-for-late-breaking-presentation-at-the-muscular-dystrophy-association-clinical--scientific-conference-in-dallas

Ifetroban demonstrated significant 5.4% improvement in cardiac function

 cumberland-q4-adj-eps-002-up-from-011-yoy-sales-1044m-up-from-935m-yoy

Cumberland (NASDAQ:CPIX) reported quarterly losses of $(0.02) per share. This is a 81.82 percent increase over losses of $(0.11...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION